Krystal Biotech, Inc. KRYS
Sales up 33.9%, free cash flow up to $188.9M
XBRL, from each 10-KThe latest figures
Price and key numbers
All key numbers (33, from the latest 10-K and 10-Q)
- EPS (ttm)
- 7.36
- Sales (ttm)
- 470.0M
- Net income (ttm)
- 225.2M
- Sales growth
- +33.9%
- EPS growth
- +128%
- Sales Q/Q
- +30.2%
- Free cash flow
- 310.1M
- Gross margin
- -
- Oper. margin
- 48.4%
- Net margin
- 47.9%
- FCF margin
- 66.0%
- ROE
- 15.7%
- ROA
- 14.2%
- R&D / sales
- 14.9%
- Dividend
- -
- Debt/Eq
- -
- Curr. ratio
- 7.89
- Cash
- 462.8M
- Op. cash flow (ttm)
- 323.9M
- EBITDA
- 167.0M
- EBITDA margin
- 42.9%
- Quick ratio
- 7.61
- ROIC
- 12.1%
- FCF after stock pay
- 134.4M
- Tax rate
- -8.1%
- Stock pay / sales
- 14.0%
- Shares out.
- 29.6M
- Shares Y/Y
- +0.7%
- Book / share
- 48.44
- Cash / share
- 15.62
- Sales / share
- 15.86
- Asset turnover
- 0.30
- Days sales out.
- 120
Hover or tap a number to see the XBRL line item and filing it comes from; click it to open that filing at SEC. What each number means. Looks wrong? Tell us.
Revenue and net income, FY2021 to FY2025
Each fiscal year from its own 10-K · XBRL
From XBRL in each 10-K. Hover a bar for the line item and filing.
What the balance sheet holds, per share
Net current asset value and tangible book value, FY2025 · 10-K XBRL, no share price used
- + Shareholders' equity $1.2B
- = Tangible book value $1.2B
Net current asset value is current assets minus all liabilities (the long-term ones too), so it is what would be left from the short-term assets after everything owed is paid; it is blank for a bank, which reports no current assets. Tangible book value is shareholders' equity minus goodwill and other intangible assets; equity includes any preferred stock. Both are divided by the diluted weighted-average share count of the same fiscal year. Red bars are amounts taken off, or a negative result.
KRYS against Health care peers
Among the 162 companies, the better end on the right. The band holds the middle half; the line is the median.
| Company | Revenue (ttm) | Sales growthFY | Gross marginttm | Net marginttm | ROEttm | FCF marginttm | Debt / equitylatest |
|---|---|---|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | $470.0M | +33.9% | - | 47.9% | 15.7% | 66.0% | - |
| PTGX Protagonist Therapeutics, Inc | $551.7M | -89.4% | - | 62.0% | 31.5% | 19.8% | - |
| ADMA Adma Biologics, Inc. | $519.2M | +19.6% | 68.5% | 35.1% | 41.6% | 25.6% | 0.45 |
| WGS GeneDx Holdings Corp. | $460.8M | +40.0% | 68.7% | -24.1% | -45.4% | -22.0% | 0.61 |
| ZLAB Zai Lab Ltd | $441.7M | +15.3% | 53.4% | -44.9% | -35.2% | -37.0% | 0.45 |
| TWST Twist Bioscience Corp | $431.8M | +20.3% | 52.0% | -31.7% | -30.7% | -21.6% | - |
Where the return on equity comes from
DuPont: net margin × asset turnover × leverage, FY2025 against FY2023 · 10-K XBRL, year-end balances
The three parts multiply to the return on equity. A higher return from leverage alone means more debt or less equity (buybacks shrink equity), not a better business. Year-end balances as filed, not averages, so each number is one line of one 10-K; hover a box for its XBRL tags.
Profitability
-
Net margin above the peer median47.9% vs 6.8%
-
Return on equity above 15%15.7%
-
A profit in 3 of 5 years
Cash and shareholders
-
Free cash flow positive in 2 of 5 years$188.9M last year
-
Share count up over 4 years+34.9%
-
Cash from operations below net income$200.9M vs $204.8M
Each tick is a fact with a fixed rule (on /methodology), not a score or advice. A check without the numbers it needs is left out.
Income statement, balance sheet and cash flow
Statements · XBRL, each 10-K and 10-Q
KRYS's income statement, balance sheet and cash flow as reported to the SEC in XBRL, one column per fiscal year, the last 10. Hover a number to see the line item and filing it comes from. Where a company changed how it tags a line, the first tag it reported for that period is used. A number looks wrong? Tell us.
Income statement
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 0 | 0 | 50.7M | 290.5M | 389.1M |
| R&D | 741K | 3.2M | 7.8M | 15.6M | 17.9M | 27.9M | 42.5M | 46.4M | 53.6M | 58.0M |
| SG&A | 402K | 1.6M | 4.2M | 6.5M | 15.1M | 40.4M | 77.7M | 98.3M | 113.6M | 146.7M |
| Operating income | -1.1M | -4.8M | -11.9M | -22.1M | -33.0M | -68.3M | -145.2M | -109.6M | 65.7M | 161.3M |
| Interest expense | - | - | - | - | 0 | 1.5M | 0 | 0 | - | - |
| Pretax income | - | - | - | - | - | -69.6M | -140.0M | 12.9M | 95.4M | 189.5M |
| Income tax | - | 0 | 0 | 0 | 0 | 0 | 0 | 2.0M | 6.2M | -15.4M |
| Net income | -1.1M | -7.9M | -10.9M | -19.1M | -32.2M | -69.6M | -140.0M | 10.9M | 89.2M | 204.8M |
| EPS (diluted) | -1.31 | -1.48 | -0.97 | -1.20 | -1.71 | -3.13 | -5.49 | 0.39 | 3.00 | 6.84 |
| Diluted shares | - | - | - | - | 18.8M | 22.2M | 25.5M | 27.8M | 29.7M | 30.0M |
| Depreciation & amortization | 2K | 23K | 141K | 1.1M | 1.9M | 2.8M | 4.1M | 5.0M | 6.0M | 5.7M |
| EBITDA | -1.1M | -4.7M | -11.8M | -21.0M | -31.1M | -65.5M | -141.1M | -104.6M | 71.7M | 167.0M |
| Operating margin | - | - | - | - | - | - | - | -216.2% | 22.6% | 41.5% |
| Net margin | - | - | - | - | - | - | - | 21.6% | 30.7% | 52.6% |
| Revenue growth | - | - | - | - | - | - | - | - | +473% | +33.9% |
| EPS growth | - | - | - | - | - | - | - | - | +669% | +128% |
Balance sheet
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash | 1.9M | 49.6M | 103.7M | 187.5M | 268.3M | 341.2M | 161.9M | 358.3M | 344.9M | 496.3M |
| Short-term investments | - | - | 8.1M | 6.2M | 3.0M | 96.8M | 217.3M | 173.8M | 252.7M | 331.5M |
| Receivables | - | - | - | - | - | - | 0 | 42.0M | 104.7M | 127.4M |
| Inventory | - | - | - | - | - | - | 0 | 7.0M | 26.5M | 40.5M |
| Current assets | 2.2M | 49.9M | 112.7M | 195.9M | 275.1M | 442.3M | 383.8M | 587.9M | 742.0M | 1.0B |
| Property & equipment | 13K | 200K | 3.0M | 8.5M | 30.9M | 112.4M | 161.7M | 161.2M | 155.2M | 150.8M |
| Total assets | 2.2M | 50.1M | 116.1M | 209.0M | 310.8M | 626.3M | 558.5M | 818.4M | 1.1B | 1.3B |
| Accounts payable | 42K | 193K | 888K | 1.0M | 2.1M | 8.4M | 4.0M | 4.1M | 5.0M | 3.2M |
| Current liabilities | 43K | 640K | 2.6M | 3.3M | 15.5M | 25.7M | 28.8M | 33.1M | 102.0M | 102.9M |
| Total liabilities | 1.9M | 640K | 2.9M | 6.1M | 18.8M | 32.7M | 36.2M | 39.7M | 109.5M | 114.2M |
| Shareholders' equity | 289K | 49.5M | 113.2M | 202.9M | 292.1M | 593.6M | 522.2M | 778.6M | 946.4M | 1.2B |
| Retained earnings | -1.1M | -9.1M | -20.0M | -39.0M | -71.2M | -140.8M | -280.8M | -269.8M | -180.7M | 24.2M |
Cash flow
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.3M | -3.9M | -9.4M | -18.7M | -26.1M | -47.9M | -100.6M | -88.8M | 123.4M | 200.9M |
| Capital spending | 15K | 210K | 2.2M | 6.4M | 14.8M | 68.3M | 53.0M | 11.8M | 4.2M | 12.0M |
| Free cash flow | -1.3M | -4.1M | -11.7M | -25.1M | -40.9M | -116.3M | -153.5M | -100.6M | 119.2M | 188.9M |
| Stock-based pay (added back) | 33K | 246K | 792K | 1.2M | 3.3M | 15.3M | 33.2M | 39.9M | 49.1M | 54.5M |
| Free cash flow after stock pay | -1.4M | -4.3M | -12.5M | -26.3M | -44.2M | -131.6M | -186.8M | -140.5M | 70.1M | 134.4M |
| Investing cash flow | -15K | -210K | -10.3M | -5.0M | -11.2M | -226.8M | -114.1M | 82.6M | -163.4M | -58.4M |
| Financing cash flow | 3.2M | 51.8M | 73.8M | 107.5M | 118.0M | 347.7M | 35.3M | 202.8M | 27.0M | 8.7M |
Stock-based pay and leases
From EDGAR| FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based pay (expense) | 33K | 246K | 792K | 1.2M | 3.3M | 15.3M | 33.2M | 39.9M | 49.1M | 54.5M |
| Stock-based pay / revenue | - | - | - | - | - | - | - | 78.8% | 16.9% | 14.0% |
| Operating lease cost | - | - | - | - | 767K | 1.3M | 1.5M | 1.6M | 1.2M | 1.6M |
| Right-of-use assets | - | - | 1.1M | 2.7M | 3.3M | 7.2M | 8.0M | 7.0M | 6.3M | 7.2M |
| Operating lease liabilities | - | - | 1.4M | 3.3M | 3.9M | 8.0M | 8.9M | 8.1M | 7.3M | 9.3M |
From SEC's XBRL company facts (data.sec.gov). EBITDA = operating income + depreciation and amortization; free cash flow = operating cash flow - capital spending; total debt = long-term debt (with its current part) + short-term borrowings. Stock-based pay and leases are shown as the company reports them; Tickdelta does not take them out of earnings or add leases to debt. Click a number to open the filing in SEC's Inline XBRL viewer, where you can click the same number to see how it is tagged. Values a company later revised show as revised; the Revised numbers tab lists the changes.
Sources
Every figure is from the company's XBRL filed with each 10-K and 10-Q (data.sec.gov). Hover a number for its line item; click it to open the filing.
Also
Company numbers: the figures the company reports beyond the statements. Peers: ten years, side by side.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/KRYS/export.csv") into a cell.